The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10087 malaria professionals are enjoying the free benefits of MalariaWorld today

artesunate-amodiaquine

Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children

February 11, 2015 - 16:25 -- Open Access
Author(s): 
Akindeh M Nji, Innocent M Ali, Wilfred F Mbacham, et al.
Reference: 
Malaria Journal 2015, 14:27 (28 January 2015)

ASAQ and DHAP are considered safe and tolerable and are not inferior to AL in the treatment of uncomplicated P. falciparum malaria in Cameroonian children.

Person: 
Country: 
Medical Treatment: 

Efficacy of artesunate-amodiaquine for the treatment of acute uncomplicated falciparum malaria in southern Mauritania

December 22, 2014 - 09:51 -- Open Access
Author(s): 
Ouldabdallahi M, Alew I, Salem MS, dit Dialaw Ba M, Boukhary AO, Khairy ML, Aziz MB, Ringwald P, Basco LK, Niang SD, Lebatt SM
Reference: 
Malaria Journal 2014, 13 :496 (16 December 2014)

Artesunate-amodiaquine is well tolerated and highly efficacious for the treatment of uncomplicated P. falciparum malaria. In the majority of patients, fever and parasitaemia were rapidly cleared before day 3.

Medical Treatment: 

In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated falciparum malaria in children: a multisite, open-label, two-cohort, clinical trial in Mozambique

August 19, 2014 - 14:04 -- Open Access
Author(s): 
Nhama A, Bassat Q, Macete E, et al.
Reference: 
Malaria Journal 2014, 13 :309 (10 August 2014)

This study confirms that both AL and ASAQ remain highly efficacious and well tolerated for the treatment of uncomplicated malaria in Mozambican children.

Country: 
Medical Treatment: 

Safety monitoring of artemisinin combination therapy through a national pharmacovigilance system in an endemic malaria setting

February 11, 2013 - 16:03 -- Open Access
Author(s): 
Thiam S, Ndiaye J, Diallo I, Gatonga P, Fall FB, Diallo NE, Faye B, Diouf ML, Ndiop M, Diouf MB, Gaye O, Thior M
Reference: 
Malaria Journal 2013, 12:54 (5 February 2013)
MalariaWorld

In this framework, an anti-malarial pharmacovigilance plan was developed and implemented in all public health services. This study investigated the occurrence of Adverse Drug Events (ADEs) after ACT.

Medical Condition: 

Surveillance of the efficacy of artemetherlumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum among children under five in Togo, 2005-2009

October 9, 2012 - 13:34 -- Kabogo Ndegwa
Author(s): 
Dorkenoo MA, Barrette A, Agbo YM, Bogreau H, Kutoati S, Sodahlon YK, Morgah K
Reference: 
Malaria Journal 2012, 11:338 (8 October 2012)

MalariaWorldBoth formulations of artemisinin-based combination therapy were effective over time and no severe adverse events related to the treatment were reported during the studies.

Country: 
Medical Condition: 

Clinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized controlled trials in sub-Saharan Africa

August 7, 2012 - 11:48 -- Kabogo Ndegwa
Author(s): 
Zwang J, Dorsey G, Djimdé A, Karema C, Mårtensson A, Ndiaye J, Sirima SB, Olliaro P
Reference: 
Malaria Journal 2012, 11:260 (2 August 2012)

MalariaWorldASAQ was comparatively well-tolerated. Safety information is important, and must be collected and analysed in a standardized way.

Medical Condition: 

Open Access | Multiple treatment comparisons in a series of anti-malarials trials with an ordinal primary outcome and repeated treatment evaluations

May 9, 2012 - 11:00 -- Kabogo Ndegwa
Author(s): 
Whegang Youdom S, Samson A, Basco LK, Thalabard J
Reference: 
Malaria Journal 2012, 11:147 (3 May 2012)

MalariaWorldBayesian mixed treatment comparisons of a network of connected randomized trials with repeated measurements of the primary categorical outcome allowed to take into account both the individual- and between- studies sources of heterogeneity.

Organization: 
Medical Condition: 

Compliance, Safety, and Effectiveness of Fixed-Dose Artesunate-Amodiaquine for Presumptive Treatment of Non-Severe Malaria in the Context of Home Management of Malaria in Madagascar

February 2, 2012 - 11:59 -- Patrick Sampao
Author(s): 
Arsène Ratsimbasoa, Harintsoa Ravony, Didier Ménard, et al.
Reference: 
Am J Trop Med Hyg 2012 86:203-210

MalariaWorldThis study provides comprehensive data concerning the clinical cure rate obtained with artesunate-amodiaquine and evidence supporting the scaling up of home management of malaria.

Country: 
Medical Condition: 
Medical Treatment: 

Open Access | Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience

May 25, 2011 - 08:49 -- Kabogo Ndegwa
Author(s): 
Bompart F, Kiechel J, Sebbag R, Pecoul B
Reference: 
Malaria Journal 2011, 10:143 (23 May 2011)

The speed at which ASAQ Winthrop was adopted in the field shows that this drug fits the needs of patients and health authorities.

Therapeutic Efficacy and Effects of Artemether-Lumefantrine and Artesunate-Amodiaquine Coformulated or Copackaged on Malaria-Associated Anemia in Children with Uncomplicated Plasmodium falciparum Malaria in Southwest Nigeria

May 4, 2011 - 15:07 -- Patrick Sampao
Author(s): 
Grace O. Gbotosho, Akintunde Sowunmi, Titilope M. Okuboyejo, Christian T. Happi, Onikepe A. Folarin, Obaro S. Michael, AND Elsie O. Adewoye
Reference: 
Am J Trop Med Hyg, May 2011; 84: 813 - 819.

The therapeutic efficacy and effects of artemether-lumefantrine (AL) and artesunate-amodiaquine co-formulated (AAcf) or co-packaged (AAcp) on malaria-associated anemia (MAA) were evaluated in 285 children < 12 years of age with uncomplicated Plasmodium falciparum malaria randomized to receive one of the three drug combinations.

Medical Condition: 

Pages

Subscribe to RSS - artesunate-amodiaquine